Kancera's inhibitors of ROR1 show an effect on leukemia cells from patients for whom standard therapy is not currently working. Kancera's partner and co-founder Professor Håkan Mellstedt and his research group at the Karolinska University Hospital conducted the studies.
Read MoreKancera has, in collaboration with Professor Håkan Mellstedt's research group at the Karolinska Institute, developed antibodies that permit the development of a diagnostic tool to identify patient response to treatment using Kancera's ROR inhibitors.
Read MoreKancera AB (publ), Sweden, has demonstrated effect with their PFKFB3 inhibitors in cells from three different types of solid tumors. In addition to the previously reported enhancement on effects off cisplatin's effect ion gastric cancer cells, the company has...
Read MoreKancera presents the company and its projects at Cambridge Innovation Center in Boston (MA) USA on Friday April 27th, 2012. The overall topic of the seminar is "Lead Generation and Structure-Based Drug Design in Cancer Research".
Read MoreKancera announced today that American Society of Clinical Oncology has selected Kancera's ROR project for presentation at this year's major conference in Chicago on June 1-5, 2012.The scientific results will be presented by Professor Håkan Mellstedt in a paper...
Read MoreKancera today announced that its ROR inhibitor show effect in an advanced and challenging human pancreatic cancer model. In the model, the Kancera compounds show superior efficacy compared to gemcitabine, today's most commonly used treatment for pancreatic cancer. The...
Read MoreJanuary 1 - December 31, 2011 All figures relate to the Kancera Group unless otherwise specified. Kancera's acquisition of iNovacia AB was completed on February 17, 2011 and iNovacia AB's operations are therefore included in the financial statements with...
Read MoreOn February 8th Kancera's CEO, Dr. Thomas Olin, presented the company and new data in its ROR inhibitor project on the "6th Swiss-Scandinavian Bio-Business Seminar" in Zurich. In his presentation Dr. Olin described how Kancera, in collaboration with...
Read MoreKancera reports that the company has registered a patent application (EP12153357) for new substances that prevents the ability of the cancer to survive. The new patent is based on Kancera's ROR technology directed against both leukemia and solid tumors....
Read MoreToday Kanceras Chief Scientific Officer, Professor Lars Ährlund-Richter, presents the company and its PFKFB3 inhibitor project at the World Cancer Metabolism Summit in Washington. The meeting brings together world experts in oncology from both the pharmaceutical industry and academia....
Read More